Lisinopril side effects: what 304,208 FDA adverse event reports show
Drug class
Angiotensin converting enzyme (ace) inhibitor
Who reports
304,208 reports · 61% serious · 25,263 with death outcome · 52% female
Used for
Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial.
What it is
Lisinopril is a dipeptide. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor.
Boxed warning
FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Intestinal angioedema | 265 | 86.6 72.2–103.9ROR 86.7 · calibrated p 4e-7 ✓ | 38.2 EB05 34.5 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | serious n=264 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Lupus vulgaris | 529 | 54.9 48.9–61.5ROR 55.0 · calibrated p 8e-6 ✓ | 30.6 EB05 28.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=529 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 262 | 44.2 37.8–51.7ROR 44.3 · calibrated p 3e-5 ✓ | 27.0 EB05 24.4 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=262 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Subcutaneous drug absorption impaired | 203 | 40.6 34.1–48.3ROR 40.6 · calibrated p 5e-5 ✓ | 25.6 EB05 22.8 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=203 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Chronic kidney disease-mineral and bone disorder | 386 | 38.3 33.8–43.4ROR 38.3 · calibrated p 7e-5 ✓ | 24.7 EB05 22.7 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=386 | not reported in cached trials |
| Deep vein thrombosis postoperative | 667 | 35.2 32.1–38.7ROR 35.3 · calibrated p 1e-4 ✓ | 23.4 EB05 22.0 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=667 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Neurologic neglect syndrome | 179 | 32.1 26.8–38.3ROR 32.1 · calibrated p 2e-4 ✓ | 22.0 EB05 19.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=179 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 639 | 31.7 28.8–34.8ROR 31.8 · calibrated p 2e-4 ✓ | 21.8 EB05 20.4 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=635 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| C-reactive protein | 276 | 29.8 25.9–34.4ROR 29.9 · calibrated p 3e-4 ✓ | 20.9 EB05 18.9 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious n=276 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 939 | 29.4 27.2–31.7ROR 29.5 · calibrated p 3e-4 ✓ | 20.7 EB05 19.6 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=939 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Nephrogenic anaemia | 1,334 | 27.2 25.6–29.0ROR 27.4 · calibrated p 4e-4 ✓ | 19.7 EB05 18.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=1,334 | not reported in cached trials |
| Dislocation of vertebra | 622 | 26.5 24.1–29.0ROR 26.5 · calibrated p 5e-4 ✓ | 19.3 EB05 18.0 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=621 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| X-ray abnormal | 489 | 25.7 23.2–28.6ROR 25.8 · calibrated p 6e-4 ✓ | 18.9 EB05 17.5 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious n=489 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Hyperparathyroidism secondary | 682 | 25.1 23.0–27.5ROR 25.2 · calibrated p 7e-4 ✓ | 18.5 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=681 | not reported in cached trials |
| Rheumatic fever | 1,150 | 24.4 22.8–26.1ROR 24.5 · calibrated p 8e-4 ✓ | 18.1 EB05 17.3 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=1,149 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Retinitis | 410 | 22.2 19.8–24.8ROR 22.2 · calibrated p 0.001 ✓ | 16.9 EB05 15.6 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=409 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Rebound acid hypersecretion | 729 | 21.3 19.6–23.1ROR 21.3 · calibrated p 0.001 ✓ | 16.4 EB05 15.4 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=729 | not reported in cached trials |
| Carotid artery thrombosis | 198 | 20.6 17.5–24.1ROR 20.6 · calibrated p 0.002 ✓ | 15.9 EB05 14.2 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=198 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Rheumatoid factor positive | 1,235 | 18.6 17.4–19.8ROR 18.6 · calibrated p 0.003 ✓ | 14.7 EB05 14.1 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=1,235 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Facet joint syndrome | 634 | 17.1 15.7–18.7ROR 17.2 · calibrated p 0.004 ✓ | 13.8 EB05 13.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=632 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 1,411 | 16.9 15.9–17.9ROR 16.9 · calibrated p 0.004 ✓ | 13.7 EB05 13.1 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | serious PRR 13.0 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 1,428 | 16.4 15.5–17.4ROR 16.5 · calibrated p 0.005 ✓ | 13.4 EB05 12.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 12.6 · ♀ 100% (drug 52%) · 95% clinician | not reported in cached trials |
| Peripheral venous disease | 720 | 15.0 13.8–16.2ROR 15.0 · calibrated p 0.007 ✓ | 12.4 EB05 11.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=712 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Brash syndrome | 211 | 12.5 10.8–14.5ROR 12.5 · calibrated p 0.015 ✓ | 10.6 EB05 9.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=211 · ♀ 0% (drug 52%) · 100% clinician | not reported in cached trials |
| End stage renal disease | 2,831 | 12.4 11.9–12.9ROR 12.5 · calibrated p 0.015 ✓ | 10.6 EB05 10.3 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 10.0 | not reported in cached trials |
| Adjustment disorder | 200 | 12.3 10.6–14.3ROR 12.3 · calibrated p 0.016 ✓ | 10.5 EB05 9.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=195 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Angioneurotic oedema | 413 | 12.3 11.1–13.6ROR 12.3 · calibrated p 0.016 ✓ | 10.5 EB05 9.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=386 · ♀ 28% (drug 52%) · 100% clinician | not reported in cached trials |
| Angioedema (deep swelling of face/throat) | 6,693 | 12.2 11.9–12.5ROR 12.4 · calibrated p 0.015 ✓ | 10.4 EB05 10.2 · IC025 +3.3 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 13.2 · serious PRR 9.2 · ♀ 27% (drug 52%) · 94% clinician | not reported in cached trials |
| Porphyria acute | 207 | 12.0 10.3–13.9ROR 12.0 · calibrated p 0.017 ✓ | 10.2 EB05 9.1 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=206 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Helicobacter infection | 1,456 | 11.3 10.7–12.0ROR 11.4 · calibrated p 0.020 ✓ | 9.8 EB05 9.4 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 9.8 · ♀ 100% (drug 52%) · 94% clinician | not reported in cached trials |
| Muscle injury | 1,093 | 10.4 9.8–11.1ROR 10.5 · calibrated p 0.027 ✓ | 9.2 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 9.3 · ♀ 100% (drug 52%) · 92% clinician | not reported in cached trials |
| Pemphigus | 1,629 | 10.3 9.7–10.8ROR 10.3 · calibrated p 0.029 ✓ | 9.0 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 8.5 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 800 | 9.6 9.0–10.4ROR 9.7 · calibrated p 0.036 ✓ | 8.5 EB05 8.0 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=772 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| C-reactive protein abnormal | 780 | 9.4 8.7–10.2ROR 9.4 · calibrated p 0.039 ✓ | 8.4 EB05 7.9 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | serious n=777 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Chronic kidney disease | 9,125 | 9.2 9.0–9.4ROR 9.4 · calibrated p 0.039 ✓ | 8.2 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 7.5 · serious PRR 7.9 | not reported in cached trials |
| Bone erosion | 415 | 9.0 8.1–10.0ROR 9.0 · calibrated p 0.046 ✓ | 8.0 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=414 · ♀ 100% (drug 52%) · 100% clinician | not reported in cached trials |
| Folliculitis | 1,193 | 8.9 8.4–9.4ROR 8.9 · calibrated p 0.048 ✓ | 7.9 EB05 7.6 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious PRR 8.6 · ♀ 100% (drug 52%) · 92% clinician | not reported in cached trials |
| Hand deformity | 1,464 | 8.6 8.1–9.0ROR 8.6 · calibrated p 0.053 | 7.7 EB05 7.4 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious PRR 7.8 · ♀ 100% (drug 52%) · 94% clinician | not reported in cached trials |
| Essential hypertension | 289 | 8.5 7.6–9.7ROR 8.5 · calibrated p 0.055 | 7.6 EB05 6.9 · IC025 +2.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=252 | not reported in cached trials |
| Hypercholesterolaemia | 1,031 | 8.2 7.7–8.8ROR 8.2 · calibrated p 0.061 | 7.4 EB05 7.0 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 7.3 · ♀ 87% (drug 52%) | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Anaphylaxis / angioedema | 7,724 | 4.54.4–4.6 | signal |
| Kidney injury | 20,438 | 3.23.1–3.2 | signal |
| Myocardial infarction | 7,372 | 2.52.5–2.6 | signal |
| Gi bleeding | 6,342 | 2.42.4–2.5 | signal |
| Heart failure | 6,164 | 2.42.4–2.5 | signal |
| Pancreatitis | 2,737 | 2.42.3–2.5 | signal |
| Hyperglycaemia / diabetes | 11,524 | 2.32.3–2.4 | signal |
| Hyponatraemia | 2,511 | 2.22.1–2.3 | signal |
| Hypoglycaemia | 2,717 | 2.01.9–2.1 | raised |
| Arrhythmia / qt | 5,138 | 1.91.8–1.9 | raised |
| Fall / fracture | 9,686 | 1.81.7–1.8 | raised |
| Depression | 7,015 | 1.71.7–1.8 | raised |
| Stroke | 6,113 | 1.71.7–1.8 | raised |
| Anaemia | 6,738 | 1.61.5–1.6 | raised |
| Rhabdomyolysis / myopathy | 1,789 | 1.51.5–1.6 | raised |
| Serious infection | 16,275 | 1.51.4–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Lisinopril as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT02603809 — Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (N=1659, PHASE2; 156 AE terms posted; arms: Placebo; Aprocitentan 5 mg; Aprocitentan 10 mg; Aprocitentan 25 mg)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 19,914 | 1.8 1.8–1.8ROR 1.8 · calibrated p 0.855 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.8 | not reported in cached trials |
| Nausea | 18,498 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.751 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled — boxed warning exact term | age-adj. PRR 1.5 · serious PRR 1.7 | NCT02603809: 1/81 (1.2%) on Lisinopril |
| Drug ineffective (drug did not work) | 17,622 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.253 | 0.9 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.1 · serious PRR 1.0 | not reported in cached trials |
| Diarrhoea (diarrhea) | 17,312 | 1.9 1.9–1.9ROR 1.9 · calibrated p 0.906 | 1.9 EB05 1.8 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.8 | NCT02603809: 1/81 (1.2%) on Lisinopril; 1/82 (1.2%) control |
| Dyspnoea (shortness of breath) | 13,984 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.804 | 1.7 EB05 1.7 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.7 | NCT02603809: 1/81 (1.2%) on Lisinopril |
| Pain | 13,638 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.684 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled — boxed warning exact term | age-adj. PRR 1.7 · serious PRR 1.6 | NCT02603809: 1/82 (1.2%) control |
| Dizziness | 13,528 | 1.9 1.9–1.9ROR 1.9 · calibrated p 0.910 | 1.9 EB05 1.8 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | NCT02603809: 1/81 (1.2%) on Lisinopril; 1/82 (1.2%) control |
| Headache | 13,016 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.616 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.6 | NCT02603809: 4/81 (4.9%) on Lisinopril; 1/82 (1.2%) control |
| Off label use (used outside approved label) | 11,049 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.225 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.8 · serious PRR 0.9 | not reported in cached trials |
| Vomiting | 11,046 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.746 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled — boxed warning exact term | age-adj. PRR 1.6 · serious PRR 1.7 | NCT02603809: 1/82 (1.2%) control |
| Asthenia (weakness) | 10,950 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.985 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.0 | NCT02603809: 1/82 (1.2%) on Lisinopril |
| Arthralgia (joint pain) | 9,649 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.731 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.8 | NCT02603809: 1/82 (1.2%) on Lisinopril; 2/82 (2.4%) control |
| Acute kidney injury (sudden kidney damage) | 9,547 | 4.5 4.5–4.6ROR 4.7 · calibrated p 0.275 | 4.3 EB05 4.2 · IC025 +2.1 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 2.8 · serious PRR 4.1 | not reported in cached trials |
| Chronic kidney disease | 9,125 | 9.2 9.0–9.4ROR 9.4 · calibrated p 0.039 ✓ | 8.2 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 7.5 · serious PRR 7.9 | not reported in cached trials |
| Fall | 9,116 | 1.9 1.9–2.0ROR 1.9 · calibrated p 0.913 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.8 | NCT02603809: 1/81 (1.2%) on Lisinopril (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Lupus vulgaris — n=529, PRR 54.9
- Chronic kidney disease-mineral and bone disorder — n=386, PRR 38.3
- Deep vein thrombosis postoperative — n=667, PRR 35.2
- Neurologic neglect syndrome — n=179, PRR 32.1
- Adjustment disorder with depressed mood — n=639, PRR 31.7
- Nephrogenic anaemia — n=1,334, PRR 27.2
- Dislocation of vertebra — n=622, PRR 26.5
- Hyperparathyroidism secondary — n=682, PRR 25.1
- Rheumatic fever — n=1,150, PRR 24.4
- Retinitis — n=410, PRR 22.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Lisinopril (ACE inhibitors) ↔ Angioedema.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Lisinopril?
In FDA FAERS, the most frequently co-reported reaction terms for Lisinopril are fatigue, nausea, diarrhoea, dyspnoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Lisinopril have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Do FAERS signals prove that Lisinopril causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 021831ab-dfeb-40fc-aede-4aa1fbb8d918, effective 20230818; matched on
openfda.generic_name.exact:"LISINOPRIL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5362119 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,171 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
LISINOPRIL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.